TLDR Cronkhite-Canada syndrome may be more treatable and less severe than previously thought.
Cronkhite-Canada Syndrome (CCS) was a rare, non-hereditary disorder characterized by gastrointestinal polyposis, alopecia, skin hyperpigmentation, and onychodystrophy. Patients typically presented with symptoms like diarrhea, weight loss, and abdominal pain. The study emphasized the importance of early diagnosis and a multidisciplinary approach to management, including nutritional support and corticosteroids. Despite treatment, the prognosis remained poor due to complications such as infections and gastrointestinal bleeding. However, newer treatments, including mesalamine, dexamethasone, and immunosuppressive therapies, showed promise in improving outcomes. Establishing an international case registry was recommended to better understand CCS's pathophysiology, treatment, and prognosis.
5 citations,
March 2013 in “International journal of surgical pathology” Cronkhite-Canada syndrome can be diagnosed without gastrointestinal polyps if there is severe mucosal atrophy and edema.
21 citations,
January 2013 in “Clinical Endoscopy” First Korean case of Cronkhite-Canada syndrome with colon cancer and serrated adenoma.
13 citations,
June 2010 in “Journal of The American Academy of Dermatology” A man with Cronkhite-Canada syndrome had all 20 nails detach but improved with treatment.
1 citations,
June 2015 in “Australasian Journal of Dermatology” A patient with Cronkhite-Canada syndrome improved with nutritional support and steroids, but early diagnosis is key due to high mortality.
16 citations,
May 2013 in “Australasian Journal of Dermatology” Hair loss in Cronkhite-Canada syndrome is reversible by treating the gut issues and doesn't need steroid treatment for the hair itself.
6 citations,
November 2018 in “Case reports in nephrology and dialysis” Rituximab may be an effective treatment for Cronkhite-Canada syndrome with kidney disease.
October 2023 in “The American Journal of Gastroenterology” Cronkhite-Canada syndrome is rare, with high mortality and cancer risk, needing more research for treatment guidelines.